Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00860158 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
A Phase 2 study, sponsored by Noah Hahn, M.D..
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00860158: Clinical Trial Phase 2 study, sponsored by Noah Hahn, M.D..
NCT00860158 is a Phase 2 study that was terminated before completion, run by Noah Hahn, M.D.. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00860158, a Phase 2 study, was terminated before completion, sponsored by Noah Hahn, M.D..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This trial will investigate the activity of dasatinib plus LHRH analogue therapy in high-risk localized prostate cancer.
Interventions
- PROCEDURE Radical Prostatectomy
- DRUG Dasatinib
- DRUG Leuprolide Acetate (LHRH Analogue)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Why NCT00860158 stopped before completion
NCT00860158 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Radical Prostatectomy is the first listed.
NCT00860158 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00860158 about?
NCT00860158 is a clinical study titled "Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer". This trial will investigate the activity of dasatinib plus LHRH analogue therapy in high-risk localized prostate cancer.
What is the current status of trial NCT00860158?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2009-03. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00860158?
The interventions under investigation include: Radical Prostatectomy (PROCEDURE), Dasatinib (DRUG), Leuprolide Acetate (LHRH Analogue) (DRUG).
Who is sponsoring clinical trial NCT00860158?
This trial is sponsored by Noah Hahn, M.D., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00860158's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia